Using NF-κB as a molecular target for theranostics in radiation oncology research

References

• Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell109(Suppl.), S81–S96 (2002).
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell6(3), 203–208 (2004).
   PubMed Web of Science ®Google Scholar
• Lin Y, Bai L, Chen W, Xu S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets14(1), 45–55 (2010).
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell140(6), 883–899 (2010).
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-κB in cancer development and progression. Nature441(7092), 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene25(51), 6817–6830 (2006).
   PubMed Web of Science ®Google Scholar
• Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer2(4), 301–310 (2002).
   PubMed Web of Science ®Google Scholar
• Pikarsky E, Porat RM, Stein I et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature431(7007), 461–466 (2004).
   PubMed Web of Science ®Google Scholar
• Vainer GW, Pikarsky E, Ben-Neriah Y. Contradictory functions of NF-κB in liver physiology and cancer. Cancer Lett.267(2), 182–188 (2008).
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Song L, Vorontchikhina M, Feirt N, Kitajewski J, Schindler C. NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancer. J. Clin. Invest.116(11), 2955–2963 (2006).
   PubMed Web of Science ®Google Scholar
• Piret B, Schoonbroodt S, Piette J. The ATM protein is required for sustained activation of NF-κB following DNA damage. Oncogene18(13), 2261–2271 (1999).
   PubMed Web of Science ®Google Scholar
• Magne N, Toillon RA, Bottero V et al. NF-κB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett.231(2), 158–168 (2006).
   PubMed Web of Science ®Google Scholar
• Barre B, Coqueret O, Perkins ND. Regulation of activity and function of the p52 NF-κB subunit following DNA damage. Cell Cycle9(24), 4795–4804 (2010).
   PubMed Web of Science ®Google Scholar
• Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ. Active roles for inhibitory κB kinases α and β in nuclear factor-κB-mediated chemoresistance to doxorubicin. Mol. Cancer Ther.7(7), 1827–1835 (2008).
   PubMed Web of Science ®Google Scholar
• Wang W, Cassidy J. Constitutive nuclear factor-κ B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br. J. Cancer88(4), 624–629 (2003).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sasaki R, Nishimura H et al. Nuclear factor-κB expression as a novel marker of radioresistance in early-stage laryngeal cancer. Head Neck32(5), 646–655 (2010).
   PubMedGoogle Scholar
• Mi J, Zhang X, Rabbani ZN et al. RNA aptamer-targeted inhibition of NF-κ B suppresses non-small cell lung cancer resistance to doxorubicin. Mol. Ther.16(1), 66–73 (2008).
   PubMed Web of Science ®Google Scholar
• Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol. Cancer Ther.8(4), 959–970 (2009).
   PubMed Web of Science ®Google Scholar
• Sandur SK, Deorukhkar A, Pandey MK et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-κB activity. Int. J. Radiat. Oncol. Biol. Phys.75(2), 534–542 (2009).
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Kurimoto M, Nagai S et al. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-κB activation in human glioma cell lines. J. Neurosurg.110(3), 594–604 (2009).
   PubMedGoogle Scholar
• Lee CT, Park MY, Kim DR et al. Blockade of NF-κB activation by IκBα gene therapy enhances radiation sensitivity and abolishes acquired resistance to radiation. Mol. Med. Report2(3), 471–475 (2009).
   PubMedGoogle Scholar
• Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-κB inhibitor DHMEQ. Curr. Pharm. Des.15(7), 792–808 (2009).
   PubMed Web of Science ®Google Scholar
• Campbell KJ, O’Shea JM, Perkins ND. Differential regulation of NF-κB activation and function by topoisomerase II inhibitors. BMC Cancer6, 101 (2006).
   PubMedGoogle Scholar
• Blagosklonny MV, Bednarski BK, Baldwin AS Jr, Kim HJ. Addressing reported proapoptotic functions of NF-κB: targeted inhibition of canonical NF-κB enhances the apoptotic effects of doxorubicin. PLoS One4(9), e6992 (2009).
   Google Scholar
• Garg AK, Jhingran A, Klopp AH et al. Expression of nuclear transcription factor κB in locally advanced human cervical cancer treated with definitive chemoradiation. Int. J. Radiat. Oncol. Biol. Phys.78(5), 1331–1336 (2010).
   PubMed Web of Science ®Google Scholar
• Abdel-Latif MM, O’Riordan JM, Ravi N, Kelleher D, Reynolds JV. Activated nuclear factor-κ B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Dis. Esophagus18(4), 246–252 (2005).
   PubMedGoogle Scholar
• Koumakpayi IH, Le Page C, Mes-Masson AM, Saad F. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-κB signalling pathway and prognostic significance in prostate cancer. Br. J. Cancer102(7), 1163–1173 (2010).
   PubMed Web of Science ®Google Scholar
• Ross JS, Kallakury BV, Sheehan CE et al. Expression of nuclear factor-κB and I κBα proteins in prostatic adenocarcinomas: correlation of nuclear factor-κB immunoreactivity with disease recurrence. Clin. Cancer Res.10(7), 2466–2472 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang Q, Helfand BT, Jang TL et al. Nuclear factor-κB-mediated transforming growth factor-β-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin. Cancer Res.15(10), 3557–3567 (2009).
   PubMed Web of Science ®Google Scholar
• Chung CH, Aulino J, Muldowney NJ et al. Nuclear factor-κB pathway and response in a Phase 2 trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol.21(4), 864–870 (2010).
   PubMed Web of Science ®Google Scholar
• O’Neil BH, Funkhouser WK, Calvo BF et al. Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy. Int. J. Radiat. Oncol. Biol. Phys.80(3), 705–711 (2011).
   PubMedGoogle Scholar
• Korkolopoulou P, Levidou G, Saetta AA et al. Expression of nuclear factor-κB in human astrocytomas: relation to pI κBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum. Pathol.39(8), 1143–1152 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang PL, Pellitteri PK, Law A et al. Overexpression of phosphorylated nuclear factor-κ B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod. Pathol.18(7), 924–932 (2005).
   PubMedGoogle Scholar
• Jiang LZ, Wang P, Deng B et al. Overexpression of Forkhead Box M1 transcription factor and nuclear factor-κB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Hum. Pathol.42(8), 1185–1193 (2011).
   PubMed Web of Science ®Google Scholar
• Nariai Y, Mishima K, Yoshimura Y, Sekine J. FAP-1 and NF-κB expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis. Int. J. Oral. Maxillofac. Surg.40(4), 419–426 (2011).
   PubMed Web of Science ®Google Scholar
• Huang C, Huang K, Wang C et al. Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-κB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Oncol. Rep.22(1), 89–95 (2009).
   PubMedGoogle Scholar
• Li J, Jia H, Xie L et al. Association of constitutive nuclear factor-κB activation with aggressive aspects and poor prognosis in cervical cancer. Int. J. Gynecol. Cancer19(8), 1421–1426 (2009).
   PubMed Web of Science ®Google Scholar
• Puvvada SD, Funkhouser WK, Greene K et al. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology78(3–4), 181–188 (2010).
   PubMed Web of Science ®Google Scholar
• Kleinberg L, Dong HP, Holth A et al. Cleaved caspase-3 and nuclear factor-κB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum. Pathol.40(6), 795–806 (2009).
   PubMedGoogle Scholar
• Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS. Increased staining for phosphorylated AKT and nuclear factor-κB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol. Int.58(12), 749–756 (2008).
   PubMed Web of Science ®Google Scholar
• Izzo JG, Wu X, Wu TT et al. Therapy-induced expression of NF-κB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis. Esophagus22(2), 127–132 (2009).
   PubMedGoogle Scholar
• Gilmore TD, Garbati MR. Inhibition of NF-κB signaling as a strategy in disease therapy. Curr. Top Microbiol. Immunol.349, 245–263 (2011).
   PubMed Web of Science ®Google Scholar
• Shen HM, Tergaonkar V. NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis14(4), 348–363 (2009).
   PubMed Web of Science ®Google Scholar
• Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways. Nat. Rev. Drug Discov.7(12), 1031–1040 (2008).
   PubMed Web of Science ®Google Scholar
• Li F, Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta1805(2), 167–180 (2010).
   PubMed Web of Science ®Google Scholar
• Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179. J. Biol. Chem.281(47), 35764–35769 (2006).
   PubMed Web of Science ®Google Scholar
• Molckovsky A, Siu LL. First-in-class, first-in-human Phase 1 results of targeted agents: highlights of the 2008 American Society of Clinical Oncology meeting. J. Hematol. Oncol.1(1), 20 (2008).
   PubMed Web of Science ®Google Scholar
• Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and Cyclin D1. Carcinogenesis24(7), 1269–1279 (2003).
   PubMed Web of Science ®Google Scholar
• Kanai M, Yoshimura K, Asada M et al. A Phase 1/2 study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol.68(1), 157–164 (2011).
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer62(8), 1137–1141 (2010).
   PubMed Web of Science ®Google Scholar
• Sethi G, Tergaonkar V. Potential pharmacological control of the NF-κB pathway. Trends Pharmacol. Sci.30(6), 313–321 (2009).
   PubMed Web of Science ®Google Scholar
• Knisely JPS, Berkey B, Chakravarti A et al. A Phase 3 study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int. J. Radiat. Oncol. Biol. Phys.71(1), 79–86 (2008).
   PubMed Web of Science ®Google Scholar
• Ch’ang HJ, Hsu C, Chen CH, Chang YH, Chang JS, Chen LT. Phase 2 study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys.82(2), 817–825 (2011).
   PubMedGoogle Scholar
• Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin. Cancer Res.16(16), 4094–4104 (2010).
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Chen C, Rabinovitch R et al. Phase 1 trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int. J. Radiat. Oncol. Biol. Phys.78(2), 521–526 (2010).
   PubMed Web of Science ®Google Scholar
• Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets11(3), 239–253 (2011).
   PubMed Web of Science ®Google Scholar
• Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin. Genitourin. Cancer5(4), 291–294 (2007).
   PubMed Web of Science ®Google Scholar
• Hsieh CH, Jeng KS, Lin CC et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin. Drug Invest.29(1), 65–71 (2009).
   PubMed Web of Science ®Google Scholar
• Horgan AM, Dawson LA, Swaminath A, Knox JJ. Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. J. Gastrointest. Cancer doi:10.1007/s12029-010-9194-4 (2010) (Epub ahead of print).
   Google Scholar
• Echeverria V, Burgess S, Gamble-George J et al. Sorafenib inhibits nuclear factor κB, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience162(4), 1220–1231 (2009).
   PubMedGoogle Scholar
• Wu JM, Sheng H, Saxena R et al. NF-κB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett.278(2), 145–155 (2009).
   PubMed Web of Science ®Google Scholar
• Suen AW, Galoforo S, Marples B et al. Sorafenib and radiation: a promising combination in colorectal cancer. Int. J. Radiat. Oncol. Biol. Phys.78(1), 213–220 (2010).
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lin WC, Chiang IT et al. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo. Biomed. Pharmacother.66(1), 12–20 (2011).
   PubMedGoogle Scholar
• Hainsworth JD, Ervin T, Friedman E et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer116(15), 3663–3669 (2010).
   PubMed Web of Science ®Google Scholar
• Girard N, Mornex F. Sorafenib and radiotherapy association for hepatocellular carcinoma. Cancer Radiother.15(1), 77–80 (2011).
   PubMed Web of Science ®Google Scholar
• Jenkins GJ, Mikhail J, Alhamdani A et al. Immunohistochemical study of nuclear factor-κB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. J. Clin. Pathol.60(11), 1232–1237 (2007).
   PubMedGoogle Scholar
• Du J, Huo J, Shi J et al. Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica96(5), 729–737 (2011).
   PubMed Web of Science ®Google Scholar
• Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-κB associated cytokines: TNF-α, IL-1α, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol. Carcinog.44(2), 77–82 (2005).
   PubMed Web of Science ®Google Scholar
• Liu Z, Cheng M, Cao M. Potential targets for molecular imaging of apoptosis resistance in hepatocellular carcinoma. Biomed. Imag. Interv. J.7(1), e5 (2011).
   Google Scholar
• Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomed.3(2), 137–140 (2008).
   PubMed Web of Science ®Google Scholar
• Hamoudi RA, Appert A, Ye H et al. Differential expression of NF-κB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia24(8), 1487–1497 (2010).
   PubMed Web of Science ®Google Scholar
• Metelev V, Zhang S, Tabatadze D, Bogdanov A. Hairpin-like fluorescent probe for imaging of NF-κB transcription factor activity. Bioconjug. Chem.22(4), 759–765 (2011).
   PubMedGoogle Scholar
• Ho TY, Chen YS, Hsiang CY. Noninvasive nuclear factor-κB bioluminescence imaging for the assessment of host-biomaterial interaction in transgenic mice. Biomaterials28(30), 4370–4377 (2007).
   PubMedGoogle Scholar
• Vykhovanets EV, Maclennan GT, Vykhovanets OV, Cherullo EE, Ponsky LE, Gupta S. Molecular imaging of nuclear factor-κB in bladder as a primary regulator of inflammatory response. J. Urol.187(1), 330–337 (2012).
   PubMedGoogle Scholar
• Mumm JB, Oft M. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene27(45), 5913–5919 (2008).
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology121(1), 1–14 (2007).
   PubMed Web of Science ®Google Scholar
• Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ. Bowel perforation after radiotherapy in a patient receiving sorafenib. J. Clin. Oncol.26(14), 2405–2406 (2008).
   PubMed Web of Science ®Google Scholar
• Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs21(2), 206–209 (2010).
   PubMedGoogle Scholar
• Mohiuddin MM, Harmon DC, Delaney TF. Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report. J. Chemother.17(3), 343–346 (2005).
   PubMed Web of Science ®Google Scholar